F Gomes1, P Lorigan2, S Woolley3, P Foden4, K Burns3, J Yorke5, F Blackhall2. 1. Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK; Patient-Centred Research Centre, The Christie NHS Foundation Trust, Manchester, UK. Electronic address: fabio.gomes2@nhs.net. 2. Medical Oncology Department, The Christie NHS Foundation Trust, Manchester, UK; Division of Medical Sciences, University of Manchester, Manchester, UK. 3. Research & Innovation Department, The Christie NHS Foundation Trust, Manchester, UK. 4. Data Analytics Department, The Christie NHS Foundation Trust, Manchester, UK. 5. Patient-Centred Research Centre, The Christie NHS Foundation Trust, Manchester, UK; Division of Nursing, Midwifery and Social Work, University of Manchester, Manchester, UK.
Abstract
OBJECTIVE: Older cancer patients are underrepresented in the pivotal trials of checkpoint inhibitors (CPIs). This study aimed to investigate the impact of an ageing immune system on CPI-related toxicity and provide evidence for the role of geriatric assessments with CPI. METHODS: The ELDERS study is a prospective observational study with two cohorts: older (70+ years of age) and younger (<70 years of age). Patients with advanced/metastatic non-small-cell lung cancer or melanoma starting single-agent CPI were eligible. The older cohort was assessed for frailty with Geriatric-8 (G8) screening, which when positive (<15 points) was followed by a holistic set of geriatric assessments. Primary endpoint was the incidence of grade 3-5 immune-related adverse events (irAEs). RESULTS: One hundred and forty patients were enrolled with 43% being pretreated and pembrolizumab represented 92% of treatments on study. The older cohort had a significantly higher comorbidity burden (P < 0.001) and polypharmacy (P = 0.004). While 50% of older patients had a positive G8 screening, 60% on this frail subgroup had a performance status score of 0 or 1. There was no significant difference in the incidence of irAEs grade 3-5 between older and younger cohorts (18.6% versus 12.9%; odds ratio 1.55, confidence interval 95% 0.61-3.89; P = 0.353). Exposure to systemic steroids due to irAEs was numerically longer for older patients (22 versus 8 weeks; P = 0.208). A positive G8 screening predicted hospital admissions (P = 0.031) and risk of death (P = 0.01). CONCLUSIONS: The use of CPI in older patients was not associated with more high-grade toxicity. The G8 screening identified a subgroup with higher risk of AEs and its implementation should be considered in the context of CPI.
OBJECTIVE: Older cancerpatients are underrepresented in the pivotal trials of checkpoint inhibitors (CPIs). This study aimed to investigate the impact of an ageing immune system on CPI-related toxicity and provide evidence for the role of geriatric assessments with CPI. METHODS: The ELDERS study is a prospective observational study with two cohorts: older (70+ years of age) and younger (<70 years of age). Patients with advanced/metastatic non-small-cell lung cancer or melanoma starting single-agent CPI were eligible. The older cohort was assessed for frailty with Geriatric-8 (G8) screening, which when positive (<15 points) was followed by a holistic set of geriatric assessments. Primary endpoint was the incidence of grade 3-5 immune-related adverse events (irAEs). RESULTS: One hundred and forty patients were enrolled with 43% being pretreated and pembrolizumab represented 92% of treatments on study. The older cohort had a significantly higher comorbidity burden (P < 0.001) and polypharmacy (P = 0.004). While 50% of older patients had a positive G8 screening, 60% on this frail subgroup had a performance status score of 0 or 1. There was no significant difference in the incidence of irAEs grade 3-5 between older and younger cohorts (18.6% versus 12.9%; odds ratio 1.55, confidence interval 95% 0.61-3.89; P = 0.353). Exposure to systemic steroids due to irAEs was numerically longer for older patients (22 versus 8 weeks; P = 0.208). A positive G8 screening predicted hospital admissions (P = 0.031) and risk of death (P = 0.01). CONCLUSIONS: The use of CPI in older patients was not associated with more high-grade toxicity. The G8 screening identified a subgroup with higher risk of AEs and its implementation should be considered in the context of CPI.
Authors: Mintcho E Mintchev; Arjun G Kalra; Chung-Ting J Kou; James K Aden; Matthew L Bezzant; Wilfred P Dela Cruz; Adrian R Bersabe Journal: Cureus Date: 2022-04-25
Authors: Carolyn J Presley; Mostafa R Mohamed; Eva Culakova; Marie Flannery; Pooja H Vibhakar; Rebecca Hoyd; Arya Amini; Noam VanderWalde; Melisa L Wong; Yukari Tsubata; Daniel J Spakowicz; Supriya G Mohile Journal: Front Oncol Date: 2022-03-31 Impact factor: 5.738
Authors: Khalil Choucair; Abdul Rafeh Naqash; Caroline A Nebhan; Ryan Nipp; Douglas B Johnson; Anwaar Saeed Journal: Oncologist Date: 2022-09-02 Impact factor: 5.837
Authors: Cheryl P Bruijnen; José J Koldenhof; Rik J Verheijden; Frederiek van den Bos; Mariëlle H Emmelot-Vonk; Petronella O Witteveen; Karijn P M Suijkerbuijk Journal: Cancer Date: 2022-04-19 Impact factor: 6.921